Just to clarify my perspective on NTI, this is the final paragraph of my review of NTI, which went to press on 4/22/99, and was distributed by mail the following week (and then received limited distribution via photocopy by NTI with my permission in mid-May):
"If everything were to work to perfection over the rest of 1999 for NTI, one could see a severalfold increase in its stock price. But such perfection rarely, if ever, comes to pass in the neuro sector. The events to watch for will start with a partnership by mid-summer. Most critically, late in the fall, we should hear the results from the diabetic neuropathy and AIDS dementia trials for Memantine. Less crucial would be the US and European Phase III data for Alzheimers, perhaps by year-end, but more likely early in 2000. AIDS-dementia and neuropathic pain are the most important to NTI in terms of revenue potential, though the Market might not appreciate this at first glance. Success in either one guarantees the Company's success, failure in both might well spell its demise. This is an investment for those who find Internet stocks mundane; NTI will be somewhere between 0 and 5 by year end. We expect at least mixed success, our year-end target is 2.50."
There are several contributors to this thread who are very well-informed and in contact with the company....my recent postings were simply in the service of playing 'devil's advocate' a bit, tempering enthusiasm without any wish to snuff it out.
NeuroInvestment (www.neuroinvestment.com) |
